12:47 PM EDT, 07/23/2024 (MT Newswires) -- Jaguar Health ( JAGX ) shares plunged 56% Tuesday after initial results of phase 3 trial testing crofelemer for diarrhea prevention in patients getting cancer treatment failed to meet primary endpoint across all tumor types.

The trial, including 10 different tumor types, did reveal some promising signals for crofelemer in specific subgroups, including patients with breast and lung cancers, the company said.

Price: 1.88, Change: -2.39, Percent Change: -55.97